Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome
Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli, Stefania Galimberti, Shanmuganathan Chandrakasan, Federico Fraschetta, Carmen Caputo, Davide Sala, Ilaria Monti, Federica Barzaghi, Valeria Calbi, Daniele Canarutto, Giulia Consiglieri, Matteo Doglio, Francesca Fumagalli, Vera Gallo, Maddalena Migliavacca, Salvatore Marco Recupero, Francesca Tucci, Alessia Orsini, Raffaella Milani, Mariam Datukishvili, Simona De Gregori, Eugenio Montini, Paolo Silvani, Matías Soncini, Elena Tomasetto, Koen van Rossem, Laura Castagnaro, Federica Miotto, Stefano Zancan, Celeste Scotti, Sean Russell, Luigi Naldini, Fabio Ciceri, Maria Ester Bernardo, Suhag H Parikh, Maria Pia Cicalese, Alessandro Aiuti
Revista con revisión por paresUso en el mundo real
En palabras de los autores
Esta revista no permite republicar el resumen completo. Estas son las dos oraciones que eligió Pipette, citadas textualmente. El resto está en el sitio de la editorial.
Resultado principal
CONCLUSIONS: Our results show that the effects of etu-cel are consistent with a sustained clinical benefit in persons with Wiskott-Aldrich syndrome.
This approach established a systematic strategy for identifying uterus-selective tocolytics, and these findings support further preclinical development of repurposed drugs and drug combinations for the treatment of preterm labor to improve pregnancy and neonatal outcomes.
Shajila Siricilla, Christopher J. Hansen, Jeremy Staub y 18 más — Science Translational Medicine
Revista con revisión por paresUso en el mundo real
Here, we report that in the experimental autoimmune encephalitis mouse model of MS, treatment with kamuvudine-9 (K-9), an NRTI derivative with an enhanced safety profile, prevented further neurological deficits and reversed preexisting paralysis and vision loss.
Praveen Yerramothu, Kameshwari Ambati, Joseph Magagnoli y 36 más — Science Translational Medicine
Revista con revisión por paresUso en el mundo real
PonatiLink-2 outperforms clinically relevant treatments in mouse models of BCR :: ABL1 -driven cancer, both in combination with dasatinib against wild-type BCR :: ABL1 and as a single agent against ponatinib-resistant disease.
Jack W. Stevenson, Kevin Lou, Joshua A. Reynolds y 25 más — Nature
Revista con revisión por paresUso en el mundo real
Conclusions In this first-in-human study, a single suprachoroidal injection of AXT107 up to 0.5 mg was well tolerated through Week 40, with no drug-related serious adverse events, no clinically significant intraocular inflammation, and no sustained IOP elevations.
N. B. Pandey, A. C. Mirando, D. R. P. Almeida y 6 más — medRxiv
Overall, this initiator-free, photo-crosslinkable GelLA-based MNs system offered a safe, efficient, and user-friendly strategy for local drug delivery in the management of acute gouty arthritis.
Jianhua Zhang, Hengjie Zhang, Tianyou Wang y 6 más — Science Advances
Revista con revisión por paresUso en el mundo real